CS MEDICA A/S: Update on IPR rights
CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces that an additional five Intellectual Property Rights (IPR) registrations have been made for CANNASEN, and the Company hereby provides an update on the Company’s IPR and trademark.CS MEDICA’s product line, CANNASEN® CBD is the world’s first over-the-counter medical technical treatment products with cannabinoids. Intellectual Property Rights (IPR) is a key element for CS MEDICA to ensure economic growth and is continually extended when entering new markets. CS MEDICA can now confirm that the Company has officially completed an